European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-18

European Modular Education and Training Programme in Safety Sciences for Medicines

Cel

Background:
In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines.

Scope and objectives:
We present a new and unique pan-European education and training network, which solves this shortfall by developing and establishing a comprehensive modular Education and Training Programme in Safety Sciences for Medicines (SafeSciMET). This programme will fulfil the needs of pharmaceutical industry, regulatory authorities and academia. The network, consisting of top institutes for drug safety education and research, proposes a new type, high quality and sustainable programme for education and training in Safety Sciences for Medicines (S2M). The tailor-made training modules will encompass the safety, ethical, regulatory and societal aspects in all phases of drug development, with emphasis on integrative, translational and 3Rs aspects of drug safety assessment. Individual safety professionals who wish to address specific knowledge gaps will be able to follow single modules. The modular set up also provides an excellent opportunity for following dedicated sub-sets of modules, to be accredited for Continuing Professional Development (CPD). Scientists successfully completing the full programme, including an integrative MSc-thesis, will be awarded with an accredited Master of Advanced Safety Sciences of Medicines (M4S2M). All training modules and procedures will be aligned with the Bologna process.

Principle learning outcomes are novel competences in translational safety sciences, leading to safety scientists who are able to perform holistic and critical evaluations of the safety of drug candidates and new medicines by linking of animal and patient data.

Dziedzina nauki

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

IMI-JU-01-2008
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Koordynator

F. HOFFMANN-LA ROCHE AG
Wkład UE
Brak danych
Adres
GRENZACHERSTRASSE 124
4070 Basel
Szwajcaria

Zobacz na mapie
Region
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Manfred Kansy (Dr.)
Kierownik naukowy
Manfred Kansy (Dr.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (32)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 25 Marca 2022

Moja broszura

Permalink: https://cordis.europa.eu/project/id/115012/pl

European Union, 2024